ICER will assess the comparative clinical effectiveness and value of treatments for peanut allergy. This evidence review will examine two new technologies to induce immune tolerance — Viaskin® Peanut (DBV Technologies) and AR101 (Aimmune Therapeutics) — as well as non-commercialized oral immunotherapy (OIT). Viaskin® Peanut is currently undergoing FDA review with an approval decision expected in mid-2019, and Aimmune Therapeutics has filed their application with the FDA for approval of AR101, with a decision expected by August 2019. This list is tentative and subject to change.
For questions, please contact Celia Segel, Director of Comparative Effectiveness Research Policy Development, at email@example.com.